Understanding FCRL1: A Potential Drug Target and Biomarker (G115350)

Target Name: FCRL1

NCBI ID: G115350

FCRL1

Understanding FCRL1: A Potential Drug Target and Biomarker

FCRL1 (Focal Constriction of Renal Microcirculation) is a protein that is expressed in the kidney and is known to play a role in the regulation of blood flow to the kidneys. Several variants of FCRL1 have been identified, including FCRL1 variant 1 (FCRL1-1) and FCRL1 variant 2 (FCRL1-2), which differ in their structure and function. While the exact function of FCRL1 is not well understood, it is possible that it may be a drug target or biomarker.

FCRL1 is a member of the superfamily of finger proteins, which are characterized by the presence of a critical domain that is responsible for the formation of a well-mediated contact between the protein and its ligand. The FCRL1 domain is characterized by a unique amino acid sequence that is composed of a series of cysteine residues that are involved in the formation of a hydrophobic core. This core is thought to play a critical role in the protein's stability and functions.

FCRL1 has been shown to be involved in the regulation of renal blood flow in several types of animals, including mice and guinea pigs. It has been shown to play a role in the regulation of angiogenesis, which is the process by which new blood vessels are formed in response to increased blood flow. In addition, FCRL1 has been shown to be involved in the regulation of fibrosis, which is the process by which connective tissue cells become abnormally organized and can cause a variety of diseases, including cancer.

While the exact function of FCRL1 is not well understood, it is possible that it may be a drug target or biomarker. For example, FCRL1 has been shown to be involved in the regulation of blood pressure, which is a critical factor in the development and progression of many diseases, including heart disease and diabetes. It is possible that drugs that target FCRL1 may be effective in treating these diseases. In addition, FCRL1 has been shown to be involved in the regulation of insulin sensitivity, which is an important factor in the development of type 2 diabetes. It is possible that drugs that target FCRL1 may be effective in treating this disease.

FCRL1 has also been shown to be involved in the regulation of inflammation, which is a critical factor in the development and progression of many diseases, including autoimmune diseases and inflammatory bowel disease. It is possible that drugs that target FCRL1 may be effective in treating these diseases.

In conclusion, FCRL1 is a protein that is expressed in the kidney and is known to play a role in the regulation of blood flow to the kidneys. Several variants of FCRL1 have been identified, including FCRL1-1 and FCRL1-2, which differ in their structure and function. While the exact function of FCRL1 is not well understood, it is possible that it may be a drug target or biomarker. Further research is needed to fully understand the role of FCRL1 in the regulation of renal blood flow and other processes.

Protein Name: Fc Receptor Like 1

Functions: May function as an activating coreceptor in B-cells. May function in B-cells activation and differentiation

The "FCRL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FCRL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets